Figure 1.
IFNL4 genotypes and clinical outcomes in the BOSON study. (A) OR graph showing the impact of IFNL4 genotype on SVR during therapy in chronic HCV patients from the BOSON study (DAA only arms). (B) Summary data from gene expression studies of peripheral blood from patients with cirrhosis taken at baseline. Venn diagram shows differentially regulated genes in IFNL4 CC and non‐CC patients (adjusted P value <0.05) when compared to common referenced healthy control group (n = 8).